SCHEMBL4309236

SCHEMBL4309236

COc1ccc2nc(-c3ccc(CCCO)cc3)c(=O)n(CC(=O)N(CCC(C)C)CCC(C)C)c2c1

nearest known ligand 0.54

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
MC4R P32245 3/20 0.43
SCD O00767 2/20 0.40
MC5R P33032 1/20 0.40
MC3R P41968 1/20 0.40
MC1R Q01726 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4310494 0.86 MC4R (0.42) MC4RMC5RMC3RMC1R
SCHEMBL4310974 0.85 SCD (0.39) SCD
SCHEMBL4311710 0.85 AKR1B10 (0.49)
SCHEMBL4312795 0.83 SCD (0.43) SCD
SCHEMBL4303684 0.81 MC4R (0.42) MC4RMC5RMC3RMC1R
SCHEMBL4315051 0.80 MC4R (0.46) MC4RMC5RMC3RMC1R
SCHEMBL4307235 0.79 MC4R (0.42) MC4RMC5RMC3RMC1R
SCHEMBL4703677 0.76 MC4R (0.55) MC4RMC5RMC3RMC1R
SCHEMBL6047818 0.76 MC4R (0.48) MC4RMC5RMC3RMC1R
SCHEMBL4307737 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090062280-A1 Ophthalmic Compositions for Treating Ocular Hypertension MERCK SHARP & DOHME CORP. 2009-03-05 US claimed
US-20090062280-A1 Ophthalmic Compositions for Treating Ocular Hypertension MERCK SHARP & DOHME CORP. 2009-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062280-A1 Ophthalmic Compositions for Treating Ocular Hypertension KCNN3, KCNN1, KCNN2 MC4R 1820/4885SCD 4403/4885MC5R 1150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.